论文部分内容阅读
Ｒｅｔｉｎｏｉｄｓ能抑制包括乳腺癌在内的上皮源性肿瘤细胞的生长，但这种抑制作用主要表现在ＥＲ（＋）的乳腺癌细胞，而Ｅｍ（—）的乳腺癌细胞对Ｒｅｔｉｎｏｉｄｓ则无反应。Ｒｅｔｉｎｏｉｄｓ的核受体有两大类６种（ＲＡＲｓ和ＲＸＲｓ）。作者检测了６种不同的乳腺癌细胞株和１８例乳腺癌标本ＲＡＲｓ的ｍＲＮＡ表达，发现无论是细胞株还是肿瘤标本，ＥＲ（＋）的ＲＡＲαｍＲＮＡ的表达均要明显高于ＥＲ（—）者（Ｐ＜０．００５）；ＲＡＲβ ｍＲＮＡ的表达则都很低，ＲＡＲγｍＲＮＡ的表达在肿瘤中都很高，和ＥＲ状态无关。ＲＸＲｓｍＲＮＡ的表达中，ＲＸＲα在所有的标本中都表达，ＲＸＲγ则几乎检测不到。实验结果提示了这样一种可能，即Ｒｅｔｉｎｏｉｄｓ抑制乳腺癌细胞生长主要通过ＲＡＲα所致。所以，检测肿瘤标本中的ＲＡＲα的水平对Ｒｅｔｉｎｏｄｓ的临床治疗具有指导意义。
Retinoids can inhibit the growth of epithelial-derived tumor cells including breast cancer, but this inhibition is mainly manifested in ER(+) breast cancer cells, while Em(-) breast cancer cells do not respond to Retinoids. Retinoids have two major classes of nuclear receptors (RARs and RXRs). The authors detected the mRNA expression of RARs in 6 different breast cancer cell lines and 18 breast cancer specimens and found that the ER (+) RARα mRNA expression was significantly higher than that of ER (-) in both cell lines and tumor samples ( P<0.005); RARβ mRNA expression was very low, and RARγ mRNA expression was high in tumors regardless of ER status. In the expression of RXRs mRNA, RXRα was expressed in all specimens and RXRγ was almost undetectable. The experimental results suggest the possibility that Retinoids inhibit the growth of breast cancer cells mainly through RARα. Therefore, detecting the level of RARα in tumor specimens has guiding significance for the clinical treatment of Retinods.